Anzeige
Mehr »
Login
Freitag, 10.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
100 % Anstieg in zwei Tagen: Das technische Signal, das Wall Streets Bären in Panik versetzt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
183 Leser
Artikel bewerten:
(1)

Sweegen's Signature Stevia Approved in Colombia

Finanznachrichten News

Approval opens door for more food and beverage sugar reduction solutions.

Rancho Santa Margarita, Calif., April 05, 2022footprint in Latin America after Colombia approved its stevia sweeteners made by bioconversion, a method producing clean and non-GMO ingredients. Sweegen's rebaudiosides E and I will now join the already approved D and M.

"Latin America is one of our most important markets globally," said Luca Giannone, senior vice president of global sales. "The continuous development of our Signature sweeteners and sweetener system demonstrates our commitment to investing in new technologies for helping brands tackle sugar reduction challenges and replace sugar in better-for-you food and beverages in Colombia."

Triggered by rising levels of obesity, Colombia has undergone a nutrition transition. The country has prioritized the health and well-being of children and families by adopting policies to address the obesity epidemic. Colombia's Ministry of Health has prioritized sugar reduction by exploring sugar-sweetened beverage (SSB) taxes to mandatory front-of-pack warning labels through legislative, and public media pushes. The country joins the growing list of Latin American countries prioritizing health, including Brazil, Chile, Uruguay, Peru, and Mexico.

In South America, 52% of consumers say they are looking to moderate sugar intake in soft drinks, according to FMCG Gurus 2021. Colombia ranks third in the region for new product launches in soft drinks and fourth for sales value in 2018, following Brazil and Argentina, as reported by Innova Market Insights.

"As new product launches have increased in recent years, brands have a clear opportunity to create healthy innovative food and beverages, replacing up to 100% sugar with Sweegen's Signature steviaand sweetener system," said Giannone.

"The regulatory development is good news for Sweegen to introduce more steviol glycosides made by bioconversion. It also gives consumer packaged goods (CPGs) direct access to Sweegen's Signature sweeteners without waiting for additional product registration in Colombia," said Hadi Omrani, senior director of technical and regulatory affairs.

New generation rebaudiosides made by bioconversion produce clean sweetener molecules like rebaudiosides B, D, E, I, M, and N, originally found in small quantities in the stevia leaf. They impart a clean sugar-like taste with a better sensory profile and are highly sought-after by food and beverage manufacturers in countries with regulatory approvals.

As Colombia traverses health and wellness improvement, brands now have less pressure to navigate sugar reduction solutions. Sweegen is a resource of expertise for brands to collaborate on new and exciting foods and beverages that resonate with consumers. Sweegen's LATAM Innovation Studio, located in Mexico City, serves the entire region. It is one of many global creative centers home to product developers exploring sweet taste solutions, local consumer insights, and collaborating on new or reformulated products with Sweegen's expert food and applications team.

"Brands have the excellent opportunity to adopt a healthy profile and broaden their product offerings to consumers increasingly interested in better-for-you foods and beverages," said Steven Chen, Sweegen's chief executive officer. "We're ready to help brands navigate the future of healthy food and beverages."

###

About Sweegen

Sweegen provides sweet taste solutions for food and beverage manufacturers around the world.

We are on a mission to reduce the sugar and artificial sweeteners in our global diet. Partnering with customers, we create delicious zero-sugar products that consumers love. With the best next-generation stevia sweeteners in our portfolio, such as Bestevia Rebs B, D, E, I, M, and N, along with our deep knowledge of flavor modulators and texturants, Sweegen delivers market-leading solutions that customers want, and consumers prefer. Be well. Choose well.

For more information, please contact info@sweegen.com and visit Sweegen's website, www.sweegen.com.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains forward-looking statements, including, among other statements, statements regarding the future prospects for Reb M stevia leaf sweetener. These statements are based on current expectations but are subject to certain risks and uncertainties, many of which are difficult to predict and are beyond the control of Sweegen, Inc.

Relevant risks and uncertainties include those referenced in the historic filings of Sweegen, Inc. with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements, and, therefore, should be carefully considered. Sweegen, Inc. assumes no obligation to update any forward-looking statements due to new information or future events or developments.

Attachment

  • Colombia approved Sweegen's Signature Stevia (https://ml.globenewswire.com/Resource/Download/6d9cdc2e-7c49-45c9-886d-830520c1aa5a)

© 2022 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.